Cytogenetic abnormalities and therapy-related myelodysplastic syndromes in rheumatic disease

Arthritis and Rheumatism

Volumn 41, Issue 8, 1998, Pages 1493-1496

  McCarthy, Conor J ^a,b   Sheldon, Susan ^a   Ross, Charles W ^a   McCune, W Joseph ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE;

ADULT; AGED; ARTICLE; CHROMOSOME 7; CHROMOSOME DELETION 5; CLINICAL ARTICLE; CYTOGENETICS; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; HUMAN; MALE; MYELODYSPLASTIC SYNDROME; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RHEUMATIC DISEASE;

ADULT; AGED; ALKYLATING AGENTS; CHLORAMBUCIL; CHROMOSOME ABERRATIONS; CHROMOSOME DISORDERS; CHROMOSOMES, HUMAN, PAIR 5; CHROMOSOMES, HUMAN, PAIR 7; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; GENE DELETION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KARYOTYPING; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RHEUMATIC DISEASES;

EID: 0031825511     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199808)41:8<1493::AID-ART21>3.0.CO;2-5     Document Type: Article

References (16)

1. Bloomfield CD. Chromosome abnormalities in secondary myelodysplastic syndromes. Scand J Haematol 1997;45 Suppl:82-90.
2. Rowley JD, Golomb HM, Vardimam JW. Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood 1981;58:759-67.
3. Anderson RL, Bagby GCJ, Magenis RE, Koler RD. Therapy-related preleukemic syndrome. Cancer 1980;47:1867-71.
4. Richert-Boe KE. Hematologic complications of rheumatic disease. Hematol Oncol Clin North Am 1987;1:307-20.
5. Castro M, Conn DL, Su DWP, Carton JP. Rheumatic manifestations in myelodysplastic syndromes. J Rheumatol 1997;18:721-7.
6. Kuzmich PD, Ecker GA, Karsh J. Rheumatic manifestations in patients with myelodysplastic syndromes. J Rheumatol 1994;21: 1649-54.
7. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Gatlin DAG, Granlick HR. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99.
8. LeBeau MM. Deletions of chromosome 5 in malignant myeloid disorders. Cancer Surv 1992;15:143-59.
9. Kantarjian HM, Estey EH, Keating MJ. Treatment of therapy-related leukemia and myelodysplastic syndrome. Hematol Oncol Clin North Am 1993;7:81-107.
10. Kantarjian HM, Keating MJ. Therapy-related leukemia and myelodysplastic syndrome. Semin Oncol 1987;14:435-43.
11. Blayney DW, Longo DL, Young RC, Greene MH, Hubbard SM, Postal MG, et al. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N Engl J Med 1987;316:710-4.
12. Lynch JP, McCune WJ. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med 1997;155:395-420.
13. Moder KG, Tefferi A, Cohen MD, Menke DM, Luthra HS. Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study. Am J Med 1995;99: 276-81.
14. - anomaly. Cancer Genet Cytogenet 1985;74:8-12.
15. Nagarajan L, Zhao L, Lu X, Warrington JA, Washmuth JJ, Siciliano M, et al. 5q-chromosome. Cancer Genet Cytogenet 1994;74:8-12.
16. Boultwood J, Rack K, Kelly S, Madden J, Sakaguchi AY, Wang L-M, et al. Loss of both CSF1R (FMS) alleles in patients with myelodysplasia and chromosome 5 deletion. Proc Natl Acad Sci U S A 1991;88:6176-80.